Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05403866 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects
A Phase 2 study, sponsored by Lumosa Therapeutics Co..
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT05403866 is a Phase 2 study that has completed, run by Lumosa Therapeutics Co.. The registered enrollment target is 89 participants.
The verdict
NCT05403866, a Phase 2 study, has completed, sponsored by Lumosa Therapeutics Co..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
Interventions
- DRUG Placebo
- DRUG LT3001 Drug Product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2022-08-17 |
| Est. Completion | 2025-05-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05403866
The ClinicalTrials.gov registry entry for NCT05403866 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumosa Therapeutics Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05403866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05403866 about?
NCT05403866 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects". This is a phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of multiple doses of LT3001 drug product in subjects with acute ischemic stroke (AIS)
What is the current status of trial NCT05403866?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2022-08-17. Estimated completion is 2025-05-23.
What interventions are being tested in trial NCT05403866?
The interventions under investigation include: Placebo (DRUG), LT3001 Drug Product (DRUG).
Who is sponsoring clinical trial NCT05403866?
This trial is sponsored by Lumosa Therapeutics Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.